"Blessed are those who are the sons of KCN, DLB, PSB, WRR, BMT, PAW, DAE, ENJ, EJC, LEO, ABSIII, SVL, DWCM and other select fathers, for theirs is the Kingdom of Big Pharma."Is that comment true, from a supply perspective?
Using those two comments' named groups as a guide, I tallied as many groups as I could. (I was not able to get to the KCN or the Grubbs group website.) There were 135 graduate students and 171 postdoctoral fellows in residence.*
How many people are immediately eligible for Ph.D. senior scientist positions in industry? Well, of course all the postdocs. Probably no more 20% of the graduate students (how many are 5th years? Hard to tell.) Okay, that's about 198 people. How many of those people are going to go to academia? Probably no more than 20%. That cuts the pool down to about 160 postdocs and new Ph.Ds who are out there, vying for entry-level positions in the pharmaceutical industry.
With that very crude number in mind and the relative paucity of openings in medicinal and process chemistry in Big Pharma, my conclusion is this: Big Pharma's chemistry openings could easily be filled with only the workers from the most elite groups in organic chemistry.
*Feel free to check my math -- I did it pretty rushed, and I'll revisit and double check tonight.